Risk of Hemolytic Anemia in IBD Patients with Glucose-6-Phosphate Dehydrogenase Deficiency Treated with Mesalamine: Results of a Retrospective-Prospective and Ex Vivo Study

Background: Mesalamine is one of the most-used drugs in inflammatory bowel disease (IBD), especially ulcerative colitis. Regulatory agencies have listed mesalamine as an unsafe drug in subjects with glucose-6-phosphate dehydrogenase (G6PD) deficiency based on the risk of hemolysis, although scientif...

Descripción completa

Detalles Bibliográficos
Autores principales: Dore, Maria Pina, Tomassini, Giulia, Rocchi, Chiara, Bulajic, Milutin, Carta, Monica, Errigo, Alessandra, Dimaggio, Alberto, Padedda, Federica, Pes, Giovanni Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381559/
https://www.ncbi.nlm.nih.gov/pubmed/37510911
http://dx.doi.org/10.3390/jcm12144797

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381559/
https://www.ncbi.nlm.nih.gov/pubmed/37510911
http://dx.doi.org/10.3390/jcm12144797

Ejemplares similares